Congestive heart failure, a condition caused by a malfunctioning heart that is unable to pump enough blood and oxygen to meet the body’s needs, is an increasingly important cause of cardiovascular morbidity and mortality. With improvements in the care of other cardiac conditions, more patients have developed dilated cardiomyopathy, which is the final common pathway for many cardiac illnesses and a common cause of congestive heart failure.
Kalorama Information's Congestive Heart Failure, Major World Markets series looks at markets for CHF treatment in the United States, Europe, Japan and the Rest of the World. Volume II of this series looks at markets for device management of this disease in the following key categories:
Left Ventricular Assistance Devices (LVADs)
Implantable Cardioverter/Defibrillators (ICDs)
The report offers revenue breakdowns the following world markets:
Rest of World
In addition to market forecasts and current market information, this report contains a thorough review of products available on the market and profiles of key companies, including:
Aortech International, plc
Atrium Medical Corporation
ATS Medical, Inc.
Bacchus Vascular, Inc.
Berlin Heart AG
Biophan Technologies, Inc.
Cardiac Science Corporation
Cordis Corporation/Biologics Delivery Systems
CryoCath Technologies, Inc.
Impulse Dynamics USA, Inc.
Orqis Medical Corporation
St. Jude Medical, Inc.
Terumo Heart, Inc.
As part of Kalorama Information's methodology, analyst estimates are computed with intensive research of secondary data and literature, and primary research involving interviews of experts are used to test assumptions and validate models.
Product managers, business development executives, marketing executives and planners are among those who will benefit from this resource.
License Note: Kalorama Information's listed default price on its information products reflects a single user license only. Purchasing a departmental license (up to 10 users at one location) or a global site license (entire company) permits multiple individuals in the company to benefit from this resource.